CMD Bioscience LLC, a computational biotechnology firm in Orange, Conn., has taken in $150,000 of a planned $225,000 mixed offering of equity, debt, warrants and options, according to a regulatory filing.

The privately held company focuses on computer-based analysis, modeling and design of peptide structures and protein-peptide interactions, the company noted on its website.  Companies in the pharmaceutical, biotech and diagnostics sectors may then use these discoveries in their own peptide developments. The company’s lead platform, Affinity, is designed to estimate binding affinities.

SOURCE